Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
After $4.8B Amicus buy, BioMarin drops genetic disease asset
As recently as October, BioMarin said it was planning to launch a phase 2 study for the asset in the first half of 2026.
Gabrielle Masson
Dec 22, 2025 11:12am
GSK picks 1st biotech partners under $7B Flagship pact
Nov 20, 2025 6:30am
Aldeyra drops and swaps RASP assets in response to data
Oct 28, 2025 9:10am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen
Aug 29, 2025 10:59am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
